October 27th, 2014
Selections from Richard Lehman’s Literature Review: October 27th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include behavioral counseling for those with CV risk factors, long-term outcomes after stenting vs. endarterectomy for treatment of symptomatic carotid stenosis, and more.
February 25th, 2011
FDA Approves Azilsartan Medoxomil (Edarbi) for High Blood Pressure
Larry Husten, PHD
The FDA has approved azilsartan medoxomil (Edarbi, Takeda) for the treatment of high blood pressure. The new angiotensin II receptor blocker (ARB) will be available in 80 mg and 40 mg doses. The recommended dose is 80 mg once daily. The 40 mg dose is used in combination with a diuretic. The FDA said that, in clinical studies, […]
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension